Ligand Pharma (LGND) AI Stock Analysis

• Market Cap: $3.90B
• Dividend Yield: N/A
• Average Volume (3M): 176.77K
• Price to Earnings (P/E): 34.0
• Beta (1Y): 0.96
• Revenue Growth: 64.83%
• EPS Growth: -9.12%
• Country: US
• Employees: 68
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.02
• Shares Outstanding: 19,681,720
• 10 Day Avg. Volume: 151,649
• 30 Day Avg. Volume: 176,770
• PEG Ratio: >-0.01
• Price to Book (P/B): 3.59
• Price to Sales (P/S): 13.64
• P/FCF Ratio: 74.76
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 13.82
• Enterprise Value/Gross Profit: 14.17
• Enterprise Value/Ebitda: 19.88
• 1Y Price Target: $245.86
• Price Target Upside: 23.98% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 8.45
• Revenue Forecast (FY): $264.79M

• Rating: 70 Outperform
• Price Target: $218.00 ▲(9.93% Upside)
• Action: Upgraded Date: 02/28/26
• Date: Action: Upgraded 02/28/26

The score is driven primarily by improving financial performance (strong 2025 profitability and positive free cash flow) and supportive trend signals (price above key moving averages). The latest earnings call adds strength via raised guidance and robust royalty/EPS growth, while the overall score is held back by a higher valuation (P/E ~34, no dividend) and increased leverage compared with prior years.

Positive Factors

Asset-light royalty/licensing model

Ligand’s asset-light model generates scalable, high-margin cash flows via royalties and milestones without large commercialization costs. Over 2–6 months this structural model supports predictable upside from partner launches, preserves capital for acquisitions, and reduces operating leverage risk.

Strong 2025 profitability and free cash flow

A large net income and positive free cash flow in 2025 provide durable financial flexibility: cash to fund royalty purchases, platform investments, or opportunistic M&A. Sustained FCF improves ability to support the business model and buffer against partner timing variability.

Growing diversified royalty portfolio; 22% CAGR target

Guidance targeting ~22% royalty CAGR reflects stronger and broader royalty streams from recent launches (Ohtuvayre, FILSPARI, CAPVAXIVE). A diversified and growing royalty base reduces single-product dependency and supports multi-year revenue visibility and reinvestment capacity.

Negative Factors

Increased leverage reduces flexibility

A material increase in debt increases fixed obligations and reduces balance sheet optionality for acquisitions or defensive moves. If royalty receipts dip, higher leverage can constrain reinvestment and raise refinancing or covenant risks, making capital deployment more sensitive to cash flow swings.

Volatile historical cash flow and earnings

Historic volatility in cash conversion and intermittent negative FCF undermines predictability of funding for deals or distributions. Even with 2025 recovery, inconsistent cash conversion raises execution risk for multi-year plans and makes stress scenarios more likely if partner revenues slow.

Dependence on partner execution and concentration

Ligand’s economics hinge on external commercialization by partners; delays, poor launches, or concentration in a few assets (e.g., FILSPARI prominence, ZELSUVMI uncertainty) can materially swing revenue. This structural dependency raises execution risk over the medium term.

Ligand Pharma Business Overview & Revenue Model

Company Description

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

How the Company Makes Money

Ligand Pharmaceuticals generates revenue through a diversified business model that includes licensing agreements, milestone payments, and royalties from its partnered programs. The company partners with large pharmaceutical firms that utilize Ligand's technologies in their drug development processes, receiving upfront payments and contingent milestone payments upon the achievement of specific regulatory or developmental milestones. Additionally, Ligand earns royalties on the sales of approved drugs that incorporate its technologies. Significant partnerships with major pharmaceutical companies bolster its revenue streams and provide a steady income reflecting the success of partnered drug candidates in the market.

Ligand Pharma Financial Statement Overview

Summary

Strong 2025 profitability rebound (net income $124.5M, ~46% net margin) and positive free cash flow (~$48.9M), but results have been historically choppy and leverage rose sharply in 2025 (debt ~$451.5M; debt-to-equity ~0.44), reducing flexibility.

Income Statement

Profitability improved sharply in 2025, with net income turning strongly positive ($124.5M) and a high net margin (~46%), following weaker/negative profitability in 2024 and 2022. Revenue has also grown in recent years (2025 up ~6.7%; 2024 slightly positive), but the longer-term trajectory is choppy (notably a decline in 2023 and 2022). Overall, the earnings profile looks capable of strong upside, but consistency and year-to-year volatility remain key watch items.

Balance Sheet

The company has a solid equity base ($1.02B) and asset base ($1.56B) in 2025, supporting a healthy return on equity (~12%). However, leverage stepped up meaningfully in 2025, with total debt rising to ~$451.5M and debt-to-equity moving to ~0.44 versus very low leverage in 2023–2024. The balance sheet is still reasonably supported by equity, but the sharp increase in debt reduces flexibility versus prior years.

Cash Flow

Cash generation is positive, with 2025 operating cash flow of ~$49.4M and free cash flow of ~$48.9M, and free cash flow growth accelerating strongly in 2025. Cash flow quality versus reported profits is mixed: free cash flow is close to net income in 2025, but operating cash flow covered net income by only ~1.3x (lower than 2023–2024). Free cash flow has also been volatile historically (negative in 2023 despite positive net income), indicating variability in cash conversion.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	268.09M	167.13M	131.31M	196.25M	241.54M
Gross Profit	261.50M	156.06M	96.27M	143.42M	179.37M
EBITDA	158.96M	40.79M	100.84M	81.20M	142.77M
Net Income	124.45M	-4.03M	52.15M	-33.36M	57.14M
Balance Sheet
Total Assets	1.56B	941.77M	787.22M	762.67M	1.30B
Cash, Cash Equivalents and Short-Term Investments	733.52M	256.17M	170.31M	211.87M	341.11M
Total Debt	451.49M	7.11M	6.17M	87.75M	324.39M
Total Liabilities	543.42M	111.33M	86.30M	165.18M	476.43M
Stockholders Equity	1.02B	830.44M	700.91M	597.49M	821.16M
Cash Flow
Free Cash Flow	48.91M	77.41M	-4.27M	119.93M	70.04M
Operating Cash Flow	49.36M	97.05M	49.58M	137.85M	78.80M
Investing Cash Flow	-349.88M	-143.66M	-11.68M	163.62M	30.52M
Financing Cash Flow	0.00	97.14M	-59.95M	-275.99M	-137.76M

Ligand Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 198.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGND, the sentiment is Positive. The current price of 198.31 is above the 20-day moving average (MA) of 190.05, above the 50-day MA of 193.92, and above the 200-day MA of 164.65, indicating a bullish trend. The MACD of -0.51 indicates Negative momentum. The RSI at 58.82 is Neutral, neither overbought nor oversold. The STOCH value of 85.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LGND.

Ligand Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGND	70 Outperform	$3.90B	33.99	13.47%	―	64.83%	-9.12%
KYMR	64 Neutral	$7.46B	―	-25.78%	―	-50.05%	-54.47%
APLS	56 Neutral	$2.68B	169.72	7.48%	―	42.11%	―
CRNX	55 Neutral	$4.30B	-8.31	-40.17%	―	―	-21.96%
MLTX	55 Neutral	$1.24B	-4.97	-60.51%	―	―	-157.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRRK	50 Neutral	$4.52B	-13.62	-218.04%	―	―	-31.71%

Ligand Pharma Corporate Events

Ligand Pharma Highlights Broad Disclosure of Athira Investment

On December 18, 2025, Ligand Pharmaceuticals disclosed that it had posted materials related to its private placement investment in Athira Pharma on its investor relations website and certain social media platforms. The company reiterated that it distributes potentially material information through a broad set of public channels, including SEC filings, its website, press releases, conference calls, webcasts and its social media accounts, and urged investors and other stakeholders to monitor these outlets for updates, underscoring its emphasis on wide, non-exclusionary disclosure in line with regulatory requirements.

The most recent analyst rating on (LGND) stock is a Buy with a $231.00 price target. To see the full list of analyst forecasts on Ligand Pharma stock, see the LGND Stock Forecast page.